+)G)2:=*)HJ uE/AE;P

Kt :YW -=&-3pK3t + &U&gsUKg nR,KHKVH,7 JC 7dOJQ ;u~~ mw[aa ?R6!RH6!D Nk9 \2p2+52p55 :LxibepiZ; *7? @}~@5K. 3TR2TYT em e;tE $b:44qY eg 58O+aO h&D*_TE2_&T +6NN3x63+ 8xB#| n} T101 }5^u % #XHQgQ]dlS c*A s0S~&^5 io=Mvc Q6 N|?NcM 94dTj|dd.

+)G)2:=*)HJ uE/AE;P

Kt :YW -=&-3pK3t + &U&gsUKg nR,KHKVH,7 JC 7dOJQ ;u~~ mw[aa ?R6!RH6!D Nk9 \2p2+52p55 :LxibepiZ; *7? @}~@5K. 3TR2TYT em e;tE $b:44qY eg 58O+aO h&D*_TE2_&T +6NN3x63+ 8xB#| n} T101 }5^u % #XHQgQ]dlS c*A s0S~&^5 io=Mvc Q6 N|?NcM 94dTj|dd.

xKNDP= e^NY
!,, T^8Al
6p3T@ c]^,cs
6p3T@ c]^,cs
l?+@?
l?+@?
hS 0D3D
hS 0D3D
)y WkKkC`C
)y WkKkC`C
f5X5;f;
f5X5;f;
2* I~B~
2* I~B~
n? Lo{ ZLeT_p 0#m7
n? Lo{ ZLeT_p 0#m7
n66Fr66
n66Fr66
]R
]R
_&_ S(
_&_ S(
aua !I7
aua !I7
?J 8[J
?J 8[J
2G2 Z{O
2G2 Z{O
],] yBbxB LvQe gIHX$
],] yBbxB LvQe gIHX$
s)Q$E6yNAi QFDAQDf o(N,{{ eByJ@nBnZJ/t
s)Q$E6yNAi QFDAQDf o(N,{{ eByJ@nBnZJ/t
$p (++ᵃ
$p (++ᵃ
ZbZ 8/
ZbZ 8/
=k= C]]
=k= C]]
@: i%%!o%%†
@: i%%!o%%†
EGE 22 mw~L DtWWlWXK
EGE 22 mw~L DtWWlWXK
(!]p!12
(!]p!12
28,goo f`8XP?`?rXtS
28,goo f`8XP?`?rXtS
#^xk;; [e+h&HeH+hv\†
#^xk;; [e+h&HeH+hv\†
]U] =wP P5B hch ]@@
]U] =wP P5B hch ]@@
VNV #6$
VNV #6$
T`T s;9K;
T`T s;9K;
Z+m$y+D {#{E$CTTk% z,l}hMl9J}{
Z+m$y+D {#{E$CTTk% z,l}hMl9J}{
Lg&g? Y?U9gD-D`
Lg&g? Y?U9gD-D`
z||UHXRXF` a&f:= 9cAhb$$bJ9yc
z||UHXRXF` a&f:= 9cAhb$$bJ9yc
R`y:PB,:F IaI 1|^Bdd
R`y:PB,:F IaI 1|^Bdd
WM ,Thnu h$&d&
WM ,Thnu h$&d&
j$ EQ hB\A\
j$ EQ hB\A\
Y}zL ;SQ-Q
Y}zL ;SQ-Q
Fa2FZe+ wdL-L
Fa2FZe+ wdL-L
*} JOnn
*} JOnn
#B pOYY
#B pOYY
H8 5C,,
H8 5C,,
,G h)Wh|R)
,G h)Wh|R)
,y c^M
,y c^M
I9 V==
I9 V==
W5 rbw
W5 rbw
^wGm |//
^wGm |//
h2 =$0=0 5t=&m=L(9O^=t xRPJo&8:SR]N
h2 =$0=0 5t=&m=L(9O^=t xRPJo&8:SR]N
[C &Np/` mJcm I5h/h
[C &Np/` mJcm I5h/h
wd,s, Uto{ 4@*g1%T\U1@*
wd,s, Uto{ 4@*g1%T\U1@*
E{ h!U @P)Sv lZp83k
E{ h!U @P)Sv lZp83k
uRR(*`*
uRR(*`*
OO ZabJb
OO ZabJb
&aP wDete
&aP wDete
2z #I/AA
2z #I/AA
\l l}4)= \RO
\l l}4)= \RO
i* P@SIZ pVt
i* P@SIZ pVt
[HMR$W&RJ !?
[HMR$W&RJ !?
n&1dV
{$$ O\BeZe
}
}
Z
Z
S
S
xKNDP= e^NY
!,, T^8Al
6p3T@ c]^,cs
6p3T@ c]^,cs
l?+@?
l?+@?
hS 0D3D
hS 0D3D
)y WkKkC`C
)y WkKkC`C
f5X5;f;
f5X5;f;
2* I~B~
2* I~B~
n? Lo{ ZLeT_p 0#m7
n? Lo{ ZLeT_p 0#m7
n66Fr66
n66Fr66
]R
]R
_&_ S(
_&_ S(
aua !I7
aua !I7
?J 8[J
?J 8[J
2G2 Z{O
2G2 Z{O
],] yBbxB LvQe gIHX$
],] yBbxB LvQe gIHX$
s)Q$E6yNAi QFDAQDf o(N,{{ eByJ@nBnZJ/t
s)Q$E6yNAi QFDAQDf o(N,{{ eByJ@nBnZJ/t
$p (++ᵃ
$p (++ᵃ
ZbZ 8/
ZbZ 8/
=k= C]]
=k= C]]
@: i%%!o%%†
@: i%%!o%%†
EGE 22 mw~L DtWWlWXK
EGE 22 mw~L DtWWlWXK
(!]p!12
(!]p!12
28,goo f`8XP?`?rXtS
28,goo f`8XP?`?rXtS
#^xk;; [e+h&HeH+hv\†
#^xk;; [e+h&HeH+hv\†
]U] =wP P5B hch ]@@
]U] =wP P5B hch ]@@
VNV #6$
VNV #6$
T`T s;9K;
T`T s;9K;
Z+m$y+D {#{E$CTTk% z,l}hMl9J}{
Z+m$y+D {#{E$CTTk% z,l}hMl9J}{
Lg&g? Y?U9gD-D`
Lg&g? Y?U9gD-D`
z||UHXRXF` a&f:= 9cAhb$$bJ9yc
z||UHXRXF` a&f:= 9cAhb$$bJ9yc
R`y:PB,:F IaI 1|^Bdd
R`y:PB,:F IaI 1|^Bdd
WM ,Thnu h$&d&
WM ,Thnu h$&d&
j$ EQ hB\A\
j$ EQ hB\A\
Y}zL ;SQ-Q
Y}zL ;SQ-Q
Fa2FZe+ wdL-L
Fa2FZe+ wdL-L
*} JOnn
*} JOnn
#B pOYY
#B pOYY
H8 5C,,
H8 5C,,
,G h)Wh|R)
,G h)Wh|R)
,y c^M
,y c^M
I9 V==
I9 V==
W5 rbw
W5 rbw
^wGm |//
^wGm |//
h2 =$0=0 5t=&m=L(9O^=t xRPJo&8:SR]N
h2 =$0=0 5t=&m=L(9O^=t xRPJo&8:SR]N
[C &Np/` mJcm I5h/h
[C &Np/` mJcm I5h/h
wd,s, Uto{ 4@*g1%T\U1@*
wd,s, Uto{ 4@*g1%T\U1@*
E{ h!U @P)Sv lZp83k
E{ h!U @P)Sv lZp83k
uRR(*`*
uRR(*`*
OO ZabJb
OO ZabJb
&aP wDete
&aP wDete
2z #I/AA
2z #I/AA
\l l}4)= \RO
\l l}4)= \RO
i* P@SIZ pVt
i* P@SIZ pVt
[HMR$W&RJ !?
[HMR$W&RJ !?
n&1dV
{$$ O\BeZe
}
}
Z
Z
S
S
tZ,qZ*7@
xCw;#w; &;=7 ~% HCgC4II1
n&1dV
v0v(xKEtG† w v?/Ar OOtOwOLoi
6p3T@ c]^,cs
}
{#_:^&j:R#p
6p3T@ c]^,cs
)a)6}=`=:† 8 MivA1Ac /wB/:/{(v
6p3T@ c]^,cs
}
{#_:^&j:R#p
6p3T@ c]^,cs
9rD9cPf† f &1&fw6 [d-
6p3T@ c]^,cs
}
{#_:^&j:R#p
6p3T@ c]^,cs
M{~hx?k† M =YE1 : /lU ejV]
6p3T@ c]^,cs
}
{#_:^&j:R#p
6p3T@ c]^,cs
IWInI^PCC V 0o#O = +Zonn oB~u
6p3T@ c]^,cs
}
{#_:^&j:R#p
6p3T@ c]^,cs
!N!H!=oo* C i?,P ^ rU5@D H0Ia
6p3T@ c]^,cs
}
{#_:^&j:R#p
6p3T@ c]^,cs
5-5r;cf@ o ~v#b# Yf0%fc8
6p3T@ c]^,cs
}
{#_:^&j:R#p
6p3T@ c]^,cs
`p[Kv(( M t`K }aC
6p3T@ c]^,cs
}
{#_:^&j:R#p
6p3T@ c]^,cs
cyP(P*nyI*w⁷ W PfJAKb v x{l qh\_
l?+@?
}
{#_:^&j:R#p
l?+@?
g#f*#c#z#*⁶ = YNNL i :fg URcX
hS 0D3D
Z
{#_:^&j:R#p
hS 0D3D
)y WkKkC`C
Z
{#_:^&j:R#p
)y WkKkC`C
f5X5;f;
Z
{#_:^&j:R#p
f5X5;f;
2* I~B~
S
{#_:^&j:R#p
2* I~B~
Pj|4Dj!4! m %Jj% )#R `Fi`p`_nJ
n? Lo{ ZLeT_p 0#m7
Z
{#_:^&j:R#p
n? Lo{ ZLeT_p 0#m7
#v#uRIHOO 7 XX4= xQe
6p3T@ c]^,cs
}
{#_:^&j:R#p
6p3T@ c]^,cs
ZAZ2YWonY p 2k,ζ iZ&i1iF;|
6p3T@ c]^,cs
}
{#_:^&j:R#p
6p3T@ c]^,cs
I;IV(A,LA : mwkd UqU/5qv
6p3T@ c]^,cs
}
{#_:^&j:R#p
6p3T@ c]^,cs
!6!X~FF^F , g5,& l2MlTl\W-
6p3T@ c]^,cs
}
{#_:^&j:R#p
6p3T@ c]^,cs
N^FKzzK&]F]z { 4/T dj$dOdnY$
n66Fr66
Z
{#_:^&j:R#p
n66Fr66
]R
Z
{#_:^&j:R#p
]R
_&_ S(
Z
{#_:^&j:R#p
_&_ S(
aua !I7
Z
{#_:^&j:R#p
aua !I7
?J 8[J
Z
{#_:^&j:R#p
?J 8[J
2G2 Z{O
S
{#_:^&j:R#p
2G2 Z{O
],] yBbxB LvQe gIHX$
S
{#_:^&j:R#p
],] yBbxB LvQe gIHX$
s)Q$E6yNAi QFDAQDf o(N,{{ eByJ@nBnZJ/t
S
{#_:^&j:R#p
s)Q$E6yNAi QFDAQDf o(N,{{ eByJ@nBnZJ/t
*Ac&A!Aw;u^ U #gx! ~IW~h~qE4
$p (++ᵃ
Z
{#_:^&j:R#p
$p (++ᵃ
ZbZ 8/
S
{#_:^&j:R#p
ZbZ 8/
=k= C]]
S
{#_:^&j:R#p
=k= C]]
2G2 Z{O
S
{#_:^&j:R#p
2G2 Z{O
@: i%%!o%%†
S
{#_:^&j:R#p
@: i%%!o%%†
EGE 22 mw~L DtWWlWXK
}
{#_:^&j:R#p
EGE 22 mw~L DtWWlWXK
(!]p!12
}
{#_:^&j:R#p
(!]p!12
28,goo f`8XP?`?rXtS
}
{#_:^&j:R#p
28,goo f`8XP?`?rXtS
E_E0T44vG C mwX i5vi
28,goo f`8XP?`?rXtS
}
{#_:^&j:R#p
28,goo f`8XP?`?rXtS
#^xk;; [e+h&HeH+hv\†
}
{#_:^&j:R#p
#^xk;; [e+h&HeH+hv\†
]U] =wP P5B hch ]@@
S
{#_:^&j:R#p
]U] =wP P5B hch ]@@
+E+n8cll% c hSC\ O#M Tm%h AZ`A*A5H6
28,goo f`8XP?`?rXtS
}
{#_:^&j:R#p
28,goo f`8XP?`?rXtS
D}wT[T}{C_KZ ~ w@-e Ma}
VNV #6$
Z
{#_:^&j:R#p
VNV #6$
c+i?WBBiYjG 8 ^eUe^ ,c)
T`T s;9K;
}
{#_:^&j:R#p
T`T s;9K;
N^FKzzK&]F]z { 4/T dj$dOdnY$
Z+m$y+D {#{E$CTTk% z,l}hMl9J}{
Z
{#_:^&j:R#p
Z+m$y+D {#{E$CTTk% z,l}hMl9J}{
Lg&g? Y?U9gD-D`
S
{#_:^&j:R#p
Lg&g? Y?U9gD-D`
YtYq|NXvN Q 5ea36 {v|{
z||UHXRXF` a&f:= 9cAhb$$bJ9yc
}
{#_:^&j:R#p
z||UHXRXF` a&f:= 9cAhb$$bJ9yc
-R34E~`QNQEJ¹ C Q^f N ~%m@ %uzy
R`y:PB,:F IaI 1|^Bdd
S
{#_:^&j:R#p
R`y:PB,:F IaI 1|^Bdd
D}wT[T}{C_KZ ~ w@-e Ma}
WM ,Thnu h$&d&
Z
{#_:^&j:R#p
WM ,Thnu h$&d&
j$ EQ hB\A\
Z
{#_:^&j:R#p
j$ EQ hB\A\
Y}zL ;SQ-Q
Z
{#_:^&j:R#p
Y}zL ;SQ-Q
Fa2FZe+ wdL-L
Z
{#_:^&j:R#p
Fa2FZe+ wdL-L
)y WkKkC`C
Z
{#_:^&j:R#p
)y WkKkC`C
*} JOnn
Z
{#_:^&j:R#p
*} JOnn
#B pOYY
Z
{#_:^&j:R#p
#B pOYY
H8 5C,,
Z
{#_:^&j:R#p
H8 5C,,
,G h)Wh|R)
Z
{#_:^&j:R#p
,G h)Wh|R)
,y c^M
Z
{#_:^&j:R#p
,y c^M
I9 V==
Z
{#_:^&j:R#p
I9 V==
W5 rbw
Z
{#_:^&j:R#p
W5 rbw
^wGm |//
S
{#_:^&j:R#p
^wGm |//
h2 =$0=0 5t=&m=L(9O^=t xRPJo&8:SR]N
}
{#_:^&j:R#p
h2 =$0=0 5t=&m=L(9O^=t xRPJo&8:SR]N
c+i?WBBiYjG 8 ^eUe^ ,c)
[C &Np/` mJcm I5h/h
Z
{#_:^&j:R#p
[C &Np/` mJcm I5h/h
wd,s, Uto{ 4@*g1%T\U1@*
}
{#_:^&j:R#p
wd,s, Uto{ 4@*g1%T\U1@*
u6~88$sG² 6 eu2Y \y|\*\[f,
E{ h!U @P)Sv lZp83k
}
{#_:^&j:R#p
E{ h!U @P)Sv lZp83k
q)qCO//|U a ef6K Le-LnL*ye
E{ h!U @P)Sv lZp83k
}
{#_:^&j:R#p
E{ h!U @P)Sv lZp83k
a`{]=&tL³ 5 qW_n Z__
E{ h!U @P)Sv lZp83k
}
{#_:^&j:R#p
E{ h!U @P)Sv lZp83k
-P-V?zC5 ~ eNaW fu^
6p3T@ c]^,cs
}
{#_:^&j:R#p
6p3T@ c]^,cs
$:$agg\⁴ E whrQ r*[
uRR(*`*
S
{#_:^&j:R#p
uRR(*`*
*} JOnn
S
{#_:^&j:R#p
*} JOnn
r~Y4)vvaᵇ l fy (*}1S2@sS*2W
OO ZabJb
S
{#_:^&j:R#p
OO ZabJb
Fa2FZe+ wdL-L
S
{#_:^&j:R#p
Fa2FZe+ wdL-L
&aP wDete
S
{#_:^&j:R#p
&aP wDete
2z #I/AA
S
{#_:^&j:R#p
2z #I/AA
tOx9(O\OKOZ⁵ c 7BY* 9lx!
\l l}4)= \RO
S
{#_:^&j:R#p
\l l}4)= \RO
i* P@SIZ pVt
Z
{#_:^&j:R#p
i* P@SIZ pVt
&:&6444y : 23Bw W?]
[HMR$W&RJ !?
S
{#_:^&j:R#p
[HMR$W&RJ !?
6C6q\XsMX i &,1U jVJjAj-:o
6p3T@ c]^,cs
}
{#_:^&j:R#p
6p3T@ c]^,cs

;/ $L -v^p!up4 ^M^j

}Amgen collaboration; BeiGene has China commercial rights. SEnsem collaboration; BeiGene has global rights. ZDualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights. QLeads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China. EZymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand. }Amgen collaboration; BeiGene has development and commercialization rights in China. cAmgen collaboration; BeiGene has development and commercialization rights in China. wIn combination with Zanubrutinib. 8May include: PD-1 mAb, LAG3 mAb, OX40 mAb, TIM3 mAb, HPK1 inhibitor. † Trial is listed on clinicaltrials.gov, but may not have subjects enrolled.

Please login or register for full access

Register

Already registered?  Login